JOSHUA NIEKRANZ: Open Payments
NPI 1396407227 · RESTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,790 in 111 payments from 19 companies in 2025. Trend: 2023 $2,169 · 2024 $3,156 · 2025 $2,790
Food & beverage: $2,790
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $345 |
| Alkermes, Inc. | 10 | $317 |
| Lundbeck LLC | 11 | $261 |
| Otsuka America Pharmaceutical, Inc. | 11 | $254 |
| Janssen Pharmaceuticals, Inc | 5 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $195 |
| Vanda Pharmaceuticals Inc. | 5 | $169 |
| Neurocrine BioSciences, Inc. | 6 | $149 |
| Axsome Therapeutics, Inc. | 7 | $137 |
| Supernus Pharmaceuticals, Inc. | 5 | $125 |
Products named: REXULTI, CAPLYTA, SPRAVATO, TRINTELLIX, ARISTADA, INGREZZA, Qelbree, LYBALVI.
Industry payments across VA — which companies pay providers there.
